+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Microbial Fermentation Technology Market Size, Share & Industry Trends Analysis Report by Application, End User, Country and Growth Forecast, 2022-2028

  • PDF Icon

    Report

  • 84 Pages
  • March 2023
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5778718
The Latin America, Middle East and Africa Microbial Fermentation Technology Market should witness market growth of 7.8% CAGR during the forecast period (2022-2028).

A wide range of drugs and vaccines, including antibody fragments, pneumococcal vaccinations, and hormones,are produced utilizing microbial fermentation processes. The utilization of high agitation rates and high-shear radial impeller systemsis made possible because bacterial cells are frequently resistant to shear damage. This increases the mass transfer potential of the fermentors, enabling them to support cultivations of quickly metabolizing, densely packed microbial cells and boosting the quantity of end product that can be created bythe bioprocesses as well.

Therefore, the market is expected to expand substantially in the upcoming years due to the growing utilization of SUB fermentors for bacterial fermentation. The usability of fermentation technology has increased, particularly in healthcare and food & beverage. In addition, substitute protein sources can be createdthrough fermentation. In order to create more tasty protein foods like tempeh and fermented tofu, it is frequently employed to transform current protein foods, especially those derived from plants like soy.

Recombinant protein is created using a more advanced fermentationto provide meat, dairy, cheese, and egg alternatives. Instances include recombinant myoglobin for faux meat, recombinant leghemoglobin for faux meat, recombinant whey for dairy replacement, and recombinant egg white. Meat has distinctive texture, flavor, color, and scent due to heme proteins, including myoglobin and hemoglobin. Even though the materials for myoglobin and leghemoglobin come from a vat rather than meat, they can still be employed to mimic this feature.

The United Arab Emirates (UAE) has a comprehensive public health system that the administration supports, as well as a rapidly growing private health sector that offers residents in the country high-quality medical care. The management of public healthcare services is the responsibility of numerous regulatory bodies at the federal and emirate levels. The Health Authority-Abu Dhabi (HAAD), Dubai Health Authority (DHA),and the Emirates Health Authority are some of the primary regulating bodies that manage the healthcare sector. In addition, growing investment in the UAE's healthcare industry will help the regional market expand.

The Brazil market dominated the LAMEA Microbial Fermentation Technology Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $692.8 million by 2028. The Argentina market is experiencing a CAGR of 8.4% during (2022-2028). Additionally, The UAE market would display a CAGR of 7.5% during (2022-2028).

Based on Application, the market is segmented into Antibiotics, Recombinant Proteins, Enzymes, Monoclonal Antibodies, Probiotics Supplements, Vaccines, Biosimilars, Small Molecules and Others. Based on End-user, the market is segmented into CMOs & CDMOs, Bio-Pharmaceutical Companies, Contract Research Organizations (CROs) and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biocon Limited, BioVectra Inc. (H.I.G. Capital, LLC), Danone S.A., F. Hoffmann-La Roche Ltd., Koninklijke DSM N.V., Lonza Group AG, Novozymes A/S (Novo Holdings A/S), Corbion N.V., and Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN).

Scope of the Study

By Application

  • Antibiotics
  • Recombinant Proteins
  • Enzymes
  • Monoclonal Antibodies
  • Probiotics Supplements
  • Vaccines
  • Biosimilars
  • Small Molecules
  • Others

By End-user

  • CMOs & CDMOs
  • Bio-Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Biocon Limited
  • BioVectra Inc. (H.I.G. Capital, LLC)
  • Danone S.A.
  • F. Hoffmann-La Roche Ltd.
  • Koninklijke DSM N.V.
  • Lonza Group AG
  • Novozymes A/S (Novo Holdings A/S)
  • Corbion N.V.
  • Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN)

Unique Offerings

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Microbial Fermentation Technology Market, by Application
1.4.2 LAMEA Microbial Fermentation Technology Market, by End-user
1.4.3 LAMEA Microbial Fermentation Technology Market, by Country
1.5 Research Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Microbial Fermentation Technology Market
Chapter 4. LAMEA Microbial Fermentation Technology Market by Application
4.1 LAMEA Antibiotics Market by Country
4.2 LAMEA Recombinant Proteins Market by Country
4.3 LAMEA Enzymes Market by Country
4.4 LAMEA Monoclonal Antibodies Market by Country
4.5 LAMEA Probiotics Supplements Market by Country
4.6 LAMEA Vaccines Market by Country
4.7 LAMEA Biosimilars Market by Country
4.8 LAMEA Small Molecules Market by Country
4.9 LAMEA Others Market by Country
Chapter 5. LAMEA Microbial Fermentation Technology Market by End-user
5.1 LAMEA CMOs & CDMOs Market by Country
5.2 LAMEA Bio-Pharmaceutical Companies Market by Country
5.3 LAMEA Contract Research Organizations (CROs) Market by Country
5.4 LAMEA Others Market by Country
Chapter 6. LAMEA Microbial Fermentation Technology Market by Country
6.1 Brazil Microbial Fermentation Technology Market
6.1.1 Brazil Microbial Fermentation Technology Market by Application
6.1.2 Brazil Microbial Fermentation Technology Market by End-user
6.2 Argentina Microbial Fermentation Technology Market
6.2.1 Argentina Microbial Fermentation Technology Market by Application
6.2.2 Argentina Microbial Fermentation Technology Market by End-user
6.3 UAE Microbial Fermentation Technology Market
6.3.1 UAE Microbial Fermentation Technology Market by Application
6.3.2 UAE Microbial Fermentation Technology Market by End-user
6.4 Saudi Arabia Microbial Fermentation Technology Market
6.4.1 Saudi Arabia Microbial Fermentation Technology Market by Application
6.4.2 Saudi Arabia Microbial Fermentation Technology Market by End-user
6.5 South Africa Microbial Fermentation Technology Market
6.5.1 South Africa Microbial Fermentation Technology Market by Application
6.5.2 South Africa Microbial Fermentation Technology Market by End-user
6.6 Nigeria Microbial Fermentation Technology Market
6.6.1 Nigeria Microbial Fermentation Technology Market by Application
6.6.2 Nigeria Microbial Fermentation Technology Market by End-user
6.7 Rest of LAMEA Microbial Fermentation Technology Market
6.7.1 Rest of LAMEA Microbial Fermentation Technology Market by Application
6.7.2 Rest of LAMEA Microbial Fermentation Technology Market by End-user
Chapter 7. Company Profiles
7.1 Biocon Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent Strategies and Developments
7.1.5.1 Acquisition and Mergers
7.2 BioVectra Inc. (H.I.G. Capital, LLC)
7.2.1 Company Overview
7.2.2 Recent Strategies and Developments
7.2.2.1 Partnerships, Collaborations, and Agreements
7.2.2.2 Product Launches and Product Expansions
7.2.2.3 Geographical Expansions
7.3 Danone S.A.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Category and Regional Analysis
7.3.4 Recent Strategies and Developments
7.3.4.1 Geographical Expansions
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 Koninklijke DSM N.V.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent Strategies and Developments
7.5.5.1 Acquisition, Joint Venture and Mergers
7.6 Lonza Group AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.7 Novozymes A/S (Novo Holdings A/S)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent Strategies and Developments
7.7.5.1 Product Launches and Product Expansions
7.8 Corbion N.V.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN)
7.9.1 Company Overview

Companies Mentioned

  • Biocon Limited
  • BioVectra Inc. (H.I.G. Capital, LLC)
  • Danone S.A.
  • F. Hoffmann-La Roche Ltd.
  • Koninklijke DSM N.V.
  • Lonza Group AG
  • Novozymes A/S (Novo Holdings A/S)
  • Corbion N.V.
  • Bangalore Biotech Labs Pvt. Ltd. (BiOZEEN)

Methodology

Loading
LOADING...